Zhengye Biotechnology Holding (ZYBT) Total Liabilities (2022 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Total Liabilities for 4 consecutive years, with $18.3 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Total Liabilities fell 6.61% year-over-year to $18.3 million in Q4 2025; TTM through Dec 2025 was $18.3 million, a 6.61% decrease from a year earlier, with the FY2025 full-year figure at $18.6 million, down 3.72% from the prior year.
• Total Liabilities was $18.3 million for Q4 2025 at Zhengye Biotechnology Holding, down from $19.5 million in the prior quarter.
• Over five years, Total Liabilities peaked at $22.3 million in Q4 2023 and troughed at -$50.2 million in Q4 2022.
• A 4-year average of $5.9 million and a median of $19.5 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 144.46% in 2023 and retreated 12.19% in 2024, its largest moves.
• Over 4 years, Total Liabilities stood at -$50.2 million in 2022, then jumped by 144.46% to $22.3 million in 2023, then dropped by 12.19% to $19.6 million in 2024, then decreased by 6.61% to $18.3 million in 2025.
• The last three Total Liabilities figures came in at $18.3 million (Q4 2025), $19.5 million (Q2 2025), and $19.6 million (Q4 2024), per Business Quant data.